KRASMutations and Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer With Lymph Node Metastases

Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone

(2008) Daniel J. Freeman et al.   Clinical Colorectal Cancer

KRAS mutations predict response to EGFR inhibitors

(2008) Mitch Raponi et al.   CURRENT OPINION IN PHARMACOLOGY

KRASMutation Signature in Colorectal Tumors Significantly Overlaps With the Cetuximab Response Signature

(2008) Aurélien de Reyniès et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations ofKRASandBRAFin Primary and Matched Metastatic Sites of Colorectal Cancer

(2008) Salvatore Artale et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the epidermal growth factor receptor in metastatic colorectal cancer

(2007) Kimmie Ng et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY